A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)
Status:
Completed
Trial end date:
2015-01-12
Target enrollment:
Participant gender:
Summary
This is an open-label, single sequence, 2-cohort, drug-drug interaction study in healthy male
and female subjects. There is no formal hypothesis, however, it is expected that the
coadministration of BMS-663068 with darunavir (DRV)/cobicistat (COBI) or COBI will increase
the systemic exposure of BMS-626529.